[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

HK1250728A1 - 新穎的il33形式、il33的突變形式、抗體、測定及其使用方法 - Google Patents

新穎的il33形式、il33的突變形式、抗體、測定及其使用方法

Info

Publication number
HK1250728A1
HK1250728A1 HK18110052.4A HK18110052A HK1250728A1 HK 1250728 A1 HK1250728 A1 HK 1250728A1 HK 18110052 A HK18110052 A HK 18110052A HK 1250728 A1 HK1250728 A1 HK 1250728A1
Authority
HK
Hong Kong
Prior art keywords
assays
antibodies
novel
methods
same
Prior art date
Application number
HK18110052.4A
Other languages
English (en)
Inventor
Emma S Cohen
David C Lowe
Robin Butler
Ian C Scott
Katherine A Vousden
Martin D Strain
Sara Carmen
Elizabeth H England
Benjamin P Kemp
David G Rees
Catherine L Overed-Sayer
Tomas M Mustelin
Matthew Sleeman
Kirsty Houslay
Original Assignee
Medimmune Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medimmune Ltd filed Critical Medimmune Ltd
Publication of HK1250728A1 publication Critical patent/HK1250728A1/zh

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52Cytokines; Lymphokines; Interferons
    • C07K14/54Interleukins [IL]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01KANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027New or modified breeds of vertebrates
    • A01K67/0275Genetically modified vertebrates, e.g. transgenic
    • A01K67/0278Knock-in vertebrates, e.g. humanised vertebrates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244Interleukins [IL]
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G01N33/6869Interleukin
    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01KANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00Genetically modified animals
    • A01K2217/07Animals genetically altered by homologous recombination
    • A01K2217/072Animals genetically altered by homologous recombination maintaining or altering function, i.e. knock in
    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01KANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00Animals characterised by species
    • A01K2227/10Mammal
    • A01K2227/105Murine
    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01KANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00Animals characterised by purpose
    • A01K2267/03Animal model, e.g. for test or diseases
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/30Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/30Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565Complementarity determining region [CDR]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567Framework region [FR]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/60Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622Single chain antibody (scFv)
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/90Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/30Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52Assays involving cytokines
    • G01N2333/54Interleukins [IL]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Zoology (AREA)
  • Environmental Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Animal Husbandry (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
HK18110052.4A 2015-03-31 2018-08-06 新穎的il33形式、il33的突變形式、抗體、測定及其使用方法 HK1250728A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562140913P 2015-03-31 2015-03-31
PCT/EP2016/056973 WO2016156440A1 (en) 2015-03-31 2016-03-30 A novel il33 form, mutated forms of il33, antibodies, assays and methods of using the same

Publications (1)

Publication Number Publication Date
HK1250728A1 true HK1250728A1 (zh) 2019-01-11

Family

ID=55640748

Family Applications (1)

Application Number Title Priority Date Filing Date
HK18110052.4A HK1250728A1 (zh) 2015-03-31 2018-08-06 新穎的il33形式、il33的突變形式、抗體、測定及其使用方法

Country Status (30)

Country Link
US (3) US10668150B2 (zh)
EP (3) EP3733701A1 (zh)
JP (3) JP6862351B2 (zh)
KR (1) KR102261618B1 (zh)
CN (1) CN108064236B (zh)
AU (3) AU2016239331C1 (zh)
BR (1) BR112017020955A2 (zh)
CA (1) CA2982400C (zh)
CL (2) CL2017002433A1 (zh)
CO (1) CO2017010753A2 (zh)
CY (1) CY1123925T1 (zh)
DK (1) DK3277717T3 (zh)
ES (1) ES2886114T3 (zh)
HK (1) HK1250728A1 (zh)
HR (1) HRP20210096T1 (zh)
HU (1) HUE053097T2 (zh)
IL (2) IL254551A0 (zh)
LT (1) LT3277717T (zh)
MX (1) MX2017012616A (zh)
MY (1) MY190209A (zh)
NZ (1) NZ736026A (zh)
PL (1) PL3277717T3 (zh)
PT (1) PT3277717T (zh)
RS (1) RS61438B1 (zh)
RU (1) RU2736299C2 (zh)
SG (1) SG11201707593UA (zh)
SI (1) SI3277717T1 (zh)
TW (1) TWI721973B (zh)
WO (1) WO2016156440A1 (zh)
ZA (1) ZA201707355B (zh)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE064292T2 (hu) 2013-12-26 2024-03-28 Mitsubishi Tanabe Pharma Corp Humán anti-IL-33 semlegesítõ monoklonális antitest
US10093730B2 (en) 2014-11-10 2018-10-09 Genentech, Inc. Anti-interleukin-33 antibodies and uses thereof
JP7231326B2 (ja) 2014-11-10 2023-03-01 ジェネンテック, インコーポレイテッド Il-33媒介性障害のための治療及び診断方法
RU2740309C2 (ru) 2016-04-27 2021-01-13 Пфайзер Инк. Антитела против il-33, композиции, способы и их применение
JOP20190093A1 (ar) 2016-10-28 2019-04-25 Lilly Co Eli أجسام مضادة لـ il-33 واستخداماتها
TWI784988B (zh) 2016-12-01 2022-12-01 美商再生元醫藥公司 治療發炎症狀的方法
IL267113B2 (en) 2016-12-21 2024-09-01 Cephalon Llc Antibodies that bind specifically to human IL-15 and their uses
SG11201909457XA (en) 2017-04-13 2019-11-28 Regeneron Pharma Treatment and inhibition of inflammatory lung diseases in patients having risk alleles in the genes encoding il33 and il1rl1
CA3066918A1 (en) 2017-06-12 2018-12-20 Bluefin Biomedicine, Inc. Anti-il1rap antibodies and antibody drug conjugates
CN115920031A (zh) 2017-08-31 2023-04-07 田边三菱制药株式会社 含有il-33拮抗剂的子宫内膜异位症治疗剂
CN107973849B (zh) * 2017-11-30 2020-07-28 畜科生物工程有限公司 一种用于增强猪疫苗免疫效果的蛋白质及其应用
WO2019183375A1 (en) * 2018-03-22 2019-09-26 Eureka Therapeutics, Inc. Antibody agents specifically recognizing monocarboxylate transporter 4 and uses thereof
IL307286A (en) 2018-04-11 2023-11-01 Regeneron Pharma Methods and preparations for quantification of IL-33
EP3851121A4 (en) * 2018-09-14 2022-06-08 Mitsubishi Tanabe Pharma Corporation PHARMACEUTICAL COMPOSITION CONTAINING A HUMAN ANTI-IL-33 MONOCLONAL ANTIBODY
CN111434687B (zh) * 2019-01-15 2022-03-11 南京赛新生物科技有限公司 一种抗体及其应用
CN111434680B (zh) * 2019-01-15 2021-11-23 南京赛新生物科技有限公司 一种与il33相关疾病的抗原表位肽及其应用
CN112300265B (zh) * 2019-07-29 2022-09-27 百奥赛图(北京)医药科技股份有限公司 Il33基因人源化的非人动物的构建方法和应用
CN110567861B (zh) * 2019-09-09 2021-12-21 浙江普罗亭健康科技有限公司 基于质谱流式检测技术筛查具有免疫原性抗原肽的试剂盒及检测方法
IL292443A (en) 2019-11-04 2022-06-01 Medimmune Ltd Methods for using IL-33 antagonists
CN114641494A (zh) 2019-11-04 2022-06-17 免疫医疗有限公司 抗-33治疗剂fpr治疗肾脏障碍
WO2021183849A1 (en) 2020-03-13 2021-09-16 Genentech, Inc. Anti-interleukin-33 antibodies and uses thereof
JP2023516497A (ja) 2020-03-13 2023-04-19 メドイミューン・リミテッド Il33にリスクアレルを有する対象を治療するための治療方法
US20230174637A1 (en) 2020-04-06 2023-06-08 Medimmune Limited Treating acute respiratory distress syndrome with il-33 axis binding antagonists
CA3181765A1 (en) 2020-05-11 2021-11-18 Medimmune Limited Formulations of anti-il-33 antibodies
CN111378037B (zh) * 2020-06-01 2020-09-01 南京诺艾新生物技术有限公司 一种抗hIL-33人源化单抗及其应用
CN116888473A (zh) 2021-02-18 2023-10-13 豪夫迈·罗氏有限公司 用于解析复杂、多步骤抗体相互作用的方法
CN113234157B (zh) * 2021-07-09 2021-09-21 上海普铭生物科技有限公司 亲和力成熟的人源化抗人il-33单克隆抗体及其应用
FI4244252T3 (fi) 2021-08-27 2024-08-29 Medimmune Ltd Kroonisen obstruktiivisen keuhkosairauden hoito anti-interleukiini-33-vasta-aineella
WO2023086807A1 (en) * 2021-11-10 2023-05-19 Genentech, Inc. Anti-interleukin-33 antibodies and uses thereof
TW202402790A (zh) 2022-03-25 2024-01-16 英商梅迪繆思有限公司 減少呼吸系統感染之方法
WO2024038186A1 (en) 2022-08-19 2024-02-22 Medimmune Limited Treatment of acute respiratory failure
WO2024038187A1 (en) 2022-08-19 2024-02-22 Medimmune Limited Assay for detection of il-33
TW202423973A (zh) 2022-08-19 2024-06-16 英商梅迪繆思有限公司 選擇患者以用il—33軸拮抗劑進行治療之方法
TW202423972A (zh) 2022-08-26 2024-06-16 英商梅迪繆思有限公司 使用抗介白素-33抗體的氣喘治療
US20240350682A1 (en) 2023-04-12 2024-10-24 Fusion Pharmaceuticals Inc. Steap2-targeted compounds and use thereof

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4474893A (en) 1981-07-01 1984-10-02 The University of Texas System Cancer Center Recombinant monoclonal antibodies
US4714681A (en) 1981-07-01 1987-12-22 The Board Of Reagents, The University Of Texas System Cancer Center Quadroma cells and trioma cells and methods for the production of same
US4741900A (en) 1982-11-16 1988-05-03 Cytogen Corporation Antibody-metal ion complexes
EP0216846B2 (en) 1985-04-01 1995-04-26 Celltech Limited Transformed myeloma cell-line and a process for the expression of a gene coding for a eukaryotic polypeptide employing same
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4873192A (en) 1987-02-17 1989-10-10 The United States Of America As Represented By The Department Of Health And Human Services Process for site specific mutagenesis without phenotypic selection
US5892019A (en) 1987-07-15 1999-04-06 The United States Of America, As Represented By The Department Of Health And Human Services Production of a single-gene-encoded immunoglobulin
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
EP0428534B1 (en) 1988-06-14 1995-03-29 Cetus Oncology Corporation Coupling agents and sterically hindered disulfide linked conjugates prepared therefrom
US4925648A (en) 1988-07-29 1990-05-15 Immunomedics, Inc. Detection and treatment of infectious and inflammatory lesions
US5601819A (en) 1988-08-11 1997-02-11 The General Hospital Corporation Bispecific antibodies for selective immune regulation and for selective immune cell binding
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5136964A (en) 1989-01-19 1992-08-11 Arnold J. Cook Warning device for windsurfing craft
US5225538A (en) 1989-02-23 1993-07-06 Genentech, Inc. Lymphocyte homing receptor/immunoglobulin fusion proteins
IE63847B1 (en) 1989-05-05 1995-06-14 Res Dev Foundation A novel antibody delivery system for biological response modifiers
WO1991000360A1 (en) 1989-06-29 1991-01-10 Medarex, Inc. Bispecific reagents for aids therapy
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
US5314995A (en) 1990-01-22 1994-05-24 Oncogen Therapeutic interleukin-2-antibody based fusion proteins
WO1991014438A1 (en) 1990-03-20 1991-10-03 The Trustees Of Columbia University In The City Of New York Chimeric antibodies with receptor binding ligands in place of their constant region
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US6172197B1 (en) 1991-07-10 2001-01-09 Medical Research Council Methods for producing members of specific binding pairs
AU667460B2 (en) 1990-10-05 1996-03-28 Medarex, Inc. Targeted immunostimulation with bispecific reagents
WO1992008802A1 (en) 1990-10-29 1992-05-29 Cetus Oncology Corporation Bispecific antibodies, method of production, and uses thereof
EP0574395B1 (en) 1990-11-09 2002-06-12 GILLIES, Stephen D. Cytokine immunoconjugates
EP0582595A1 (en) 1991-04-26 1994-02-16 Surface Active Limited Novel antibodies, and methods for their use
ATE463573T1 (de) 1991-12-02 2010-04-15 Medimmune Ltd Herstellung von autoantikörpern auf phagenoberflächen ausgehend von antikörpersegmentbibliotheken
FR2686087A1 (fr) 1992-01-13 1993-07-16 Inst Nat Sante Rech Med Nouvel antigene lymphocytaire, anticorps correspondant et leurs applications.
US6004554A (en) 1992-03-05 1999-12-21 Board Of Regents, The University Of Texas System Methods for targeting the vasculature of solid tumors
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
EP0859841B1 (en) 1995-08-18 2002-06-19 MorphoSys AG Protein/(poly)peptide libraries
US6696248B1 (en) 1995-08-18 2004-02-24 Morphosys Ag Protein/(poly)peptide libraries
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
US6897044B1 (en) 1999-01-28 2005-05-24 Biogen Idec, Inc. Production of tetravalent antibodies
EP1133565B1 (en) 1999-07-02 2010-09-22 MorphoSys AG Generation of specific binding partners binding to (poly)peptides encoded by genomic dna fragments or ests
US6849425B1 (en) 1999-10-14 2005-02-01 Ixsys, Inc. Methods of optimizing antibody variable region binding affinity
CA2401342C (en) 2000-03-03 2010-08-03 Cambridge Antibody Technology Limited Human antibodies against eotaxin and their use
WO2002102855A2 (en) 2000-11-17 2002-12-27 University Of Rochester In vitro methods of producing and identifying immunoglobulin molecules in eukaryotic cells
DE60143544D1 (de) 2000-12-12 2011-01-05 Medimmune Llc Moleküle mit längeren halbwertszeiten, zusammensetzungen und deren verwendung
US7319139B2 (en) 2001-01-29 2008-01-15 Biogen Idec, Inc. TAG-72 specific CH2 domain deleted antibodies
US20040132101A1 (en) 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
EP1532175B1 (en) 2002-03-22 2012-10-17 Aprogen, Inc. Humanized antibody and process for preparing the same
NZ549040A (en) * 2004-02-17 2009-07-31 Schering Corp Use for interleukin-33 (IL33) and the IL-33 receptor complex
PL3339445T3 (pl) * 2006-09-08 2020-12-14 Abbvie Bahamas Ltd. Białka wiążące interleukinę 13
WO2008137552A2 (en) 2007-05-02 2008-11-13 Medimmune, Llc Anti-rage antibodies and methods of use thereof
EP2069784A4 (en) * 2007-05-18 2009-11-18 Medimmune Llc IL-33 IN INFLAMMATORY DISEASE
WO2009055074A2 (en) 2007-10-25 2009-04-30 Wyeth Erbb2 binding proteins and use thereof
US8092804B2 (en) 2007-12-21 2012-01-10 Medimmune Limited Binding members for interleukin-4 receptor alpha (IL-4Rα)-173
DK2644698T3 (en) * 2010-11-17 2018-01-22 Chugai Pharmaceutical Co Ltd MULTI-SPECIFIC ANTIGEN-BINDING MOLECULE WITH ALTERNATIVE FUNCTION TO BLOOD COAGULATION FACTOR FUNCTION VIII
US8790651B2 (en) * 2011-07-21 2014-07-29 Zoetis Llc Interleukin-31 monoclonal antibody
AR091069A1 (es) 2012-05-18 2014-12-30 Amgen Inc Proteinas de union a antigeno dirigidas contra el receptor st2
JO3532B1 (ar) * 2013-03-13 2020-07-05 Regeneron Pharma الأجسام المضادة لمضاد انترلوكين-33 واستعمالاتها

Also Published As

Publication number Publication date
EP3277717A1 (en) 2018-02-07
JP6862351B2 (ja) 2021-04-21
CL2017002433A1 (es) 2018-05-04
ES2886114T3 (es) 2021-12-16
HRP20210096T1 (hr) 2021-03-05
RU2017134909A (ru) 2019-03-28
EP4374916A3 (en) 2024-08-28
EP3277717B1 (en) 2020-11-18
EP4374916A2 (en) 2024-05-29
AU2016239331A1 (en) 2017-10-26
AU2019250213A1 (en) 2019-11-07
MY190209A (en) 2022-04-05
IL254551A0 (en) 2017-11-30
CY1123925T1 (el) 2022-05-27
JP2021038226A (ja) 2021-03-11
BR112017020955A2 (pt) 2018-07-10
WO2016156440A1 (en) 2016-10-06
MX2017012616A (es) 2018-04-10
JP2024001166A (ja) 2024-01-09
RU2017134909A3 (zh) 2019-12-23
LT3277717T (lt) 2021-08-10
AU2021257881B2 (en) 2022-02-17
CN108064236A (zh) 2018-05-22
NZ736026A (en) 2023-02-24
AU2016239331B2 (en) 2019-07-25
DK3277717T3 (da) 2021-02-01
AU2016239331C1 (en) 2020-01-30
RU2736299C2 (ru) 2020-11-13
JP2018516853A (ja) 2018-06-28
US20180207265A1 (en) 2018-07-26
RS61438B1 (sr) 2021-03-31
US20240016929A1 (en) 2024-01-18
CN108064236B (zh) 2021-12-10
PL3277717T3 (pl) 2021-05-31
CA2982400C (en) 2023-10-24
US11738081B2 (en) 2023-08-29
TWI721973B (zh) 2021-03-21
SI3277717T1 (sl) 2021-03-31
AU2021257881A1 (en) 2021-11-18
CA2982400A1 (en) 2016-10-06
CO2017010753A2 (es) 2018-03-20
EP3733701A1 (en) 2020-11-04
US20200353078A1 (en) 2020-11-12
KR102261618B1 (ko) 2021-06-04
SG11201707593UA (en) 2017-10-30
US10668150B2 (en) 2020-06-02
ZA201707355B (en) 2022-06-29
CL2020002269A1 (es) 2021-01-22
HUE053097T2 (hu) 2021-06-28
TW201704259A (zh) 2017-02-01
IL280045A (en) 2021-03-01
IL280045B (en) 2021-09-30
KR20170132811A (ko) 2017-12-04
PT3277717T (pt) 2021-02-01
AU2019250213B2 (en) 2021-12-02

Similar Documents

Publication Publication Date Title
IL280045B (en) Novel form of il33, mutant forms of il33, antibodies, assays and methods for their use
IL304772A (en) Antibodies, uses and methods
IL264654B1 (en) Anti-tigit antibodies, anti-pvrig antibodies and their combinations
IL264159A (en) Anti-tim-3 antibodies
HK1243104A1 (zh) 抗fgfr2/3抗體及其使用方法
SG10201601719RA (en) Anti-LAG-3 Antibodies
GB201601073D0 (en) Antibodies
GB201621439D0 (en) IL-11Ra Antibodies
GB201403875D0 (en) Novel antibodies and uses thereof
GB201413913D0 (en) Novel antibodies and uses thereof
GB201610044D0 (en) Antibodies
IL252430A0 (en) Antibodies, uses and methods
GB201603291D0 (en) Antibodies
IL264262A (en) Antibodies against interleukin 22 receptors
GB201616699D0 (en) Antibodies
PT3178929T (pt) Novo anticorpo anti-ig(beta) humana
IL263406A (en) Anti-tnfrs25 antibodies
GB201622197D0 (en) Antibodies
GB201620414D0 (en) Antibodies
GB201615224D0 (en) Antibodies
GB201613158D0 (en) Antibodies
GB201612437D0 (en) Anti-lag-3 antibodies
TH1701000696B (th) แผ่นโลหะที่ถูกเคลือบผิว, วิธีสำหรับการผลิตสิ่งเดียวกันนั้น, และวัสดุก่อสร้างภายนอก
GB201401812D0 (en) Enzyme cascade immunoassay